Last Mile Health partners with government to deploy, support, and manage networks of community health professionals and to integrate them into the public health system. With training in maternal and child health, family planning, treatment adherence, and surveillance of epidemics, together with mentoring from nurse supervisors, these community health workers deliver quality healthcare to remote communities. In communities Last Mile Health serves, newborn mortality has decreased and the percentage of children treated for diarrhea, malaria, and pneumonia has increased. On the strength of this success, Last Mile Health is now supporting the Liberian Ministry of Health to implement the approach nationwide, preparing policy documents, training curricula, and impact measurement tools, and coordinating with NGO partners.

Launched at the 2016 World Economic Forum in Davos, INFUSE seeks tried and tested innovations that have potential to improve vaccine delivery. It then “infuses” them with capital and expertise to help take them to scale. INFUSE 2018 is calling for proven digital technology innovations that provide more effective methods of identity registration and authentication to accelerate and improve immunisation coverage and delivery.

A 2.4-mile swim, a 112-mile bicycle ride and then a full-length marathon on hot, dry ground -- with no breaks in between: the legendary Ironman triathlon in Kona, Hawaii, is a bucket list goal for champion athletes. But when Minda Dentler decided to take it on, she had bigger aspirations than just another medal around her neck. She tells the story of how she conquered this epic race, and what it inspired her to do next.

Polio can’t be cured, but it can be prevented. Two important tools help to prevent polio – two safe, effective vaccines. Find out about the oral polio vaccine and the inactivated poliovirus vaccine and their roles in the polio eradication effort.

To eradicate polio, we need to stop all strains of the virus, including vaccine-derived polioviruses. This short video explains how these rare virus strains emerge and how to stop them.

Twenty years ago, in February 1998, one of the most serious public health scandals of the 20th century was born, when researcher, Andrew Wakefield and his co-authors published a paper in the medical journal The Lancet suggesting a link between the MMR vaccine and autism. As we know, in the years that followed, Wakefield's paper was completely discredited as "an elaborate fraud" and retracted. Attempts by many other researchers to replicate his "findings" have all failed and investigations unearthed commercial links and conflicts of interests underpinning his original work. Wakefield himself was struck off the medical register. And yet, the ripples of that episode are still being felt today all over the world as a resurgent anti-vaccine movement continues to drive down inoculation rates, particularly in developed Western societies, where measles rates have rocketed particularly in Europe and the United States. But the Wakefield scandal hasn't just fostered the current ant-vax movement but has played a key role in helping to undermine trust in a host of scientific disciplines from public health research to climate science and GM technology. Through the archive, science journalist Adam Rutherford explores the continuing legacy of the anti-vaccine movement on the anniversary of one of its most notorious episodes, and explore its impact on health, on research and on culture both at home and abroad.

Today’s youth are tomorrow’s economic prosperity. What can governments do now to help young people transform the future?

How an outbreak of diphtheria in a Rohingya refugee camp in Bangladesh makes it clear that these people were living in substandard conditions before they fled Myanmar.

NFID animated public service announcement on the two types of vaccines available to prevent meningococcal disease among adolescents and young adults

"My child, my choice" is the public cry of parents who are against vaccinating their children. But that choice may be endangering thousands of others who can't receive vaccinations because they are too young or suffer from health conditions that compromise their immune systems. This video exposes the dangerous hypocrisy behind the anti-vaxxer movement in under six minutes.

This talk was given at a local TEDx event. The speaker talks about preventing chronic diseases in developing countries, with a particular focus on diabetes, one of the fastest growing health challenges in Africa.

Dr. Thomas Frieden, Director, U.S. Centers for Disease Control and Prevention, discusses the achievements of the global polio programme and the way head, focussing on India's efforts.

On September 28, CSIS hosted a major international conference that brought together polio eradication leaders for a full day of panels and discussion. Here is an interview with Michel Zaffra

MenAfriVac, a new vaccine against Meningococcal Meningitis seroptype Nm A, is expected to prevent meningitis epidemics in Africa's "meningitis belt" of 25 countries that stretch from Senegal in the west to Ethiopia in the east. Hit by epidemics every few years, the meningitis belt accounts for 95 percent of the world's meningococcal meningitis disease burden. The region's worst epidemic in recent times, the 1996 epidemic, hit more than 250,000 people in the region, killing 25,000 people and causing residual disability for 50,000 others. Besides the death and disability though, meningitis epidemics have a profound socio-political significance too. Epidemics frighten people away from work and cost large amounts of money to handle. Developed by the Meningitis Vaccine Project, a joint project of PATH and WHO, the vaccine was launched in Burkina Faso in November 2010. MenAfriVac costs less than 50 US cents per dose and is 95 percent effective. The GAVI Alliance is paying the overwhelming majority of costs to roll the vaccine out. If fully funded, GAVI expects to see 236 million people vaccinated with MenAfriVac in all 25 countries of the meningitis belt.

This documentary examines the remarkable global response to devastating meningitis A outbreaks in Africa and the rapid development of an affordable vaccine to eliminate these recurring epidemics.